Soligenix submits BARDA proposal for OrbeShield radiation exposure therapy

The development stage biopharmaceutical company Soligenix, Inc., recently announced that it has submitted a contract proposal for the development of its radiation therapy, known as OrbeShield.

Soligenix said that it was invited to submit its proposal to the U.S. Biomedical Advanced Research and Development Authority Division of Chemical, Biological, Radiological and Nuclear Medical Countermeasures.

OrbeShield is currently under development for the treatment of gastrointestinal acute radiation syndrome, which can occur after the human body is exposed to toxic levels of radiation. GI ARS affects several organ systems, including bone marrow, the gastrointestinal tract and eventually the pulmonary system.

Canine modeling of OrbeShield has shown a statistically significant increase in survival rates in animals that received the therapy up to 24 hours after being exposed to lethal doses of total body irradiation. Median survival after the radiation challenge was 87 days in the OrbeShield treated group, compared to only eight days in the placebo control group.

"We are excited about the contract proposal submission to BARDA," Soligenix President and CEO Dr. Christopher J. Schaber said. "Although there are no guarantees, we believe that we are well-positioned to receive BARDA development support for this indication allowing us to further demonstrate the growing body of compelling scientific evidence supporting OrbeShield's potential as a countermeasure for GI ARS."